Business Wire08.17.17
Corindus Vascular Robotics Inc., a developer of precision vascular robotics, has appointed John K. Bakewell to its board of directors, effective immediately. Bakewell will chair the board's Audit Committee.
"I am pleased to welcome John to our board of directors. John’s financial expertise coupled with his tremendous experience driving sustainable growth within transformational companies will be invaluable to our organization," President and CEO Mark Toland said.
Bakewell has served in executive capacities for more than two decades, building and executing operational and financial strategies for growing businesses across the healthcare sector. Over the course of his career, he has served as chief financial officer at Exact Sciences Corporation, Lantheus Holdings Inc., Interline Brands Inc., Regional Care Hospital Partners, Wright Medical Group Inc., Altra Energy Technologies Inc., Cyberonics Inc., and Zeos International Ltd. Bakewell is currently a consultant to the medical technology industry. He serves on the board of directors for both Entellus Medical Inc. and Keystone Dental Inc. He previously served on the Board of Directors of ev3 Inc. until its acquisition in 2010.
Bakewell has a bachelor of arts degree in accounting from the University of Northern Iowa and is a certified public accountant (inactive).
"I am delighted to join Corindus and am committed to its mission of bringing robotic-assisted precision and its many benefits to vascular interventions," Bakewell said. "I look forward to working with the Corindus team as the company continues to drive adoption of its technology, addressing the significant unmet needs of interventional cardiology."
Corindus Vascular Robotics Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.
"I am pleased to welcome John to our board of directors. John’s financial expertise coupled with his tremendous experience driving sustainable growth within transformational companies will be invaluable to our organization," President and CEO Mark Toland said.
Bakewell has served in executive capacities for more than two decades, building and executing operational and financial strategies for growing businesses across the healthcare sector. Over the course of his career, he has served as chief financial officer at Exact Sciences Corporation, Lantheus Holdings Inc., Interline Brands Inc., Regional Care Hospital Partners, Wright Medical Group Inc., Altra Energy Technologies Inc., Cyberonics Inc., and Zeos International Ltd. Bakewell is currently a consultant to the medical technology industry. He serves on the board of directors for both Entellus Medical Inc. and Keystone Dental Inc. He previously served on the Board of Directors of ev3 Inc. until its acquisition in 2010.
Bakewell has a bachelor of arts degree in accounting from the University of Northern Iowa and is a certified public accountant (inactive).
"I am delighted to join Corindus and am committed to its mission of bringing robotic-assisted precision and its many benefits to vascular interventions," Bakewell said. "I look forward to working with the Corindus team as the company continues to drive adoption of its technology, addressing the significant unmet needs of interventional cardiology."
Corindus Vascular Robotics Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.